ProQR Therapeutics N.V. Share Price & Technical Analysis
PRQR · $1.56 (+8.33%)
Healthcare / Biotechnology
$1.56
+8.33%
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseas…
Price chart
Seasonality
May has 1 positive and 1 negative years (last 5 years shown)
0% return in May, -6% avg return in past 3 year May month.
-13% return in 2026, 7% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -20% | 0% | 7% | 0% | 0% | – | – | – | – | – | – | – | -13% |
| 25 | -22% | 10% | -43% | 31% | 0% | 18% | 5% | 5% | -5% | 27% | -18% | -13% | -6% |
| 24 | 10% | -9% | 15% | -17% | 5% | -15% | 19% | 5% | -10% | 94% | 9% | -29% | 77% |
| 23 | -26% | 11% | -28% | 5% | -23% | -11% | -6% | 0% | -19% | -15% | 36% | 25% | -51% |
| 22 | -32% | -81% | -18% | -22% | 0% | 14% | 0% | -11% | -12% | 13% | 33% | 208% | 91% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$163.84M
P/E ratio
—
52W high
$3.10
52W low
$1.33
Volume
5,52,643
Beta
0.07
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is ProQR Therapeutics N.V. share price today?
- ProQR Therapeutics N.V. (PRQR) last traded around $1.56 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PRQR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PRQR. Download the app for real-time alerts.
- How can I analyze ProQR Therapeutics N.V. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.